Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 20/20 | 0.61 |
| ▸ | CASP6 | P55212 | 19/20 | 0.61 |
| ▸ | CASP8 | Q14790 | 19/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24381550 | 0.91 | CASP3 (0.50) | CASP3CASP6CASP8 | |
| SCHEMBL23957259 | 0.85 | CASP3 (0.62) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL23957260 | 0.84 | CASP3 (0.61) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL23957191 | 0.83 | CASP3 (0.61) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL23957233 | 0.82 | CASP3 (0.61) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL23957197 | 0.81 | CASP3 (0.62) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL23957255 | 0.81 | CASP3 (0.64) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL23957238 | 0.80 | CASP3 (0.63) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL23957207 | 0.80 | CASP3 (0.63) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL23957180 | 0.79 | CASP3 (0.55) | CASP3CASP6CASP8CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434212-B2 | Bicyclic compound as a caspase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-09-06 | — | — | US | disclosed |
| US-20210332019-A1 | Bicyclic Compound as a Caspase Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434212-B2 | Bicyclic compound as a caspase inhibitor | CASP1, CASP14, CASP2 | CASP3 9/4885CASP6 11/4885CASP8 4/4885 |
| US-20210332019-A1 | Bicyclic Compound as a Caspase Inhibitor | CASP1, CASP14, CASP2 | CASP3 9/4885CASP6 11/4885CASP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.